Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Clinical Cancer Research

• Publication date

  2000-07-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  PMID 10914735
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Oncogene].

  2019cited by this paper
• Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide

  2004cited by this paper
• Involvement of poly(ADP-ribose) polymerase in base excision repair.

  1999cited by this paper
• Relative affinities of poly(ADP-ribose) polymerase and DNA-dependent protein kinase for DNA strand interruptions.

  1999cited by this paper
• Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage.

  1999cited by this paper
• Poly (ADP-ribose) polymerase, nitric oxide and cell death.

  1999cited by this paper
• Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP).

  1998cited by this paper
• DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines.

  1998cited by this paper
• Poly(ADP-ribose) Binds to Specific Domains of p53 and Alters Its DNA Binding Functions*

  1998cited by this paper
• Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.

  1998cited by this paper
• Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

  1997cited by this paper
• Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis

  1997cited by this paper
• Defective induction but normal activation and function of p53 in mouse cells lacking poly-ADP-ribose polymerase

  1997cited by this paper
• Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells.

  1997cited by this paper
• Novel Benzimidazole and Quinazolinone Inhibitors of the DNA Repair Enzyme Poly(ADP‐ribose)polymerase*

  1996cited by this paper
• Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation.

  1996cited by this paper
• Phase I Trial and Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Topotecan Using a Five‐Day Course in Children with Refractory Solid Tumors: A Pediatric Oncology Group Study

  1996cited by this paper
• Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines.

  1996cited by this paper
• Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks.

  1995cited by this paper
• The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy.

  1995cited by this paper
• Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease.

  1995cited by this paper
• Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP).

  1995cited by this paper
• Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors.

  1995cited by this paper
• Phase I study of topotecan for pediatric patients with malignant solid tumors.

  1994cited by this paper
• Poly(ADP-ribose) polymerase: a molecular nick-sensor.

  1994cited by this paper
• Molecular and biochemical features of poly (ADP-ribose) metabolism

  1993cited by this paper
• Increased accumulation of p53 protein in cisplatin‐resistant ovarian cell lines

  1993cited by this paper
• Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

  1992cited by this paper
• New colorimetric cytotoxicity assay for anticancer-drug screening.

  1990cited by this paper
• Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells.

  1987cited by this paper
• Poly(ADP-ribose) in the cellular response to DNA damage.

  1985cited by this paper
• In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain.

  1977cited by this paper
• Splitting of the ribose-ribose linkage of poly(adenosine diphosphate-robose) by a calf thymus extract.

  1971cited by this paper

• Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma

  2025cites this paper
• Revisiting Temozolomide's role in solid tumors: Old is gold?

  2024cites this paper
• Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions

  2024cites this paper
• Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

  2023cites this paper
• Molecular and Functional Heterogeneity of Primary Pancreatic Neuroendocrine Tumors and Metastases

  2023cites this paper
• Unveiling the vulnerabilities of synthetic lethality in triple-negative breast cancer

  2023cites this paper
• Dual-target inhibitors based on PARP1: new trend in the development of anticancer research.

  2022cites this paper
• Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer

  2022cites this paper
• A novel cuproptosis-related subtypes and gene signature associates with immunophenotype and predicts prognosis accurately in neuroblastoma

  2022cites this paper
• BMX, a specific HDAC8 inhibitor, with TMZ for advanced CRC therapy: a novel synergic effect to elicit p53-, β-catenin- and MGMT-dependent apoptotic cell death

  2022cites this paper
• PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications.

  2022cites this paper
• Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

  2022cites this paper
• Poly adenosine diphosphate-ribosylation, a promising target for colorectal cancer treatment

  2021cites this paper
• Theoretical insights into molecular mechanism and energy criteria of PARP‐2 enzyme inhibition by benzimidazole analogues

  2021cites this paper
• Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers

  2021cites this paper
• Novel 4,5-dihydrospiro[benzo[c]azepine-1,1'-cyclohexan]-3(2H)-one derivatives as PARP-1 inhibitors: Design, synthesis and biological evaluation.

  2021cites this paper
• Highlights in metastatic breast cancer from the European Society for Medical Oncology Virtual Congress 2020.

  2020cites this paper
• Untangling trapped topoisomerases with tyrosyl-DNA phosphodiesterases.

  2020cites this paper
• Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair

  2020cites this paper
• Temozolomide and Pazopanib Combined with FOLFOX Regressed a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model

  2020cites this paper
• The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction.

  2020cites this paper
• Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome

  2020cites this paper
• NU1025 | MedChemExpress

  2020influential citation
• PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy

  2019cites this paper
• Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)

  2019cites this paper
• PARP Inhibition to Enhance Response to Chemotherapy

  2019cites this paper
• Update on PARP Inhibitors in Breast Cancer

  2018cites this paper
• Treatment of Rats with Hydrocortisone and Cisplatin Modulates Poly ( ADP-Ribos ) yl Polymerase 1 Activity In Liver and Thymocyte Nuclei C Research

  2018cites this paper
• A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer

  2018cites this paper
• Clinical Strategies for PARP Inhibitors beyondHomologous Recombination Deficiency

  2018cites this paper
• Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2–wild-type Triple-Negative Breast Cancer

  2017cites this paper
• Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity.

  2017cites this paper
• Therapeutic Targeting of Poly(ADP‐Ribose) Polymerase‐1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities

  2017cites this paper
• Targeting DNA Damage Response Pathways in Cancer

  2017cites this paper
• The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients, and Techniques Used to Identify Susceptible Patients.

  2017cites this paper
• Inhalational chemical exposure resulting in myelogenous leukemia

  2017cites this paper
• Prognostic and therapeutic implications of DNA repair gene mutations in advanced prostate cancer.

  2017cites this paper
• Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.

  2017cites this paper
• A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors

  2017cites this paper
• Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor

  2016cites this paper
• Understanding specific functions of PARP-2: new lessons for cancer therapy.

  2016cites this paper
• Graphical models for de novo and pathway-based network prediction over multi-modal high-throughput biological data

  2016influential citation
• Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.

  2016cites this paper
• An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors

  2016cites this paper
• PI3K-AKT-mTOR Pathway Cooperates with the DNA Damage Repair Pathway: Carcinogenesis in Triple-Negative Breast Cancers and Beyond

  2016cites this paper
• Cisplatin Modulates poly(adp-ribos)yl Polymerase 1 Inhibition and DNA Internucleosomal Fragmentation in Rat Liver Nuclei

  2016cites this paper
• Complex role of nicotinamide adenine dinucleotide in the regulation of programmed cell death pathways.

  2016cites this paper
• Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.

  2015cites this paper
• Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.

  2015cites this paper
• Trapping Poly(ADP-Ribose) Polymerase

  2015cites this paper
• Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy

  2015cites this paper
• PARP1 Inhibitors: antitumor drug design

  2015cites this paper
• Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.

  2015cites this paper
• Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status

  2015cites this paper
• Natural Product Modulators to Overcome Multidrug Resistance In Cancer

  2015cites this paper
• Age-dependentdifference in thymocyte poly (ADP-ribose) polymerase 1 inhibition afterthe in vivo treatment of rats with cisplatin

  2015cites this paper
• PARP Enzymes are Potential Targets for Cancer Chemotherapy

  2015cites this paper
• BRCA1 Mutation: A Predictive Marker for Radiation Therapy?

  2015cites this paper
• The development of PARP inhibitors in ovarian cancer: from bench to bedside

  2015cites this paper
• A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix: An NRG Oncology/Gynecologic Oncology Group Study

  2014cites this paper
• Predictive biomarkers for cancer therapy with PARP inhibitors

  2014cites this paper
• Changes in Poly(ADP-Ribosyl)ation Patterns in Workers Exposed to BTX

  2014cites this paper
• Cancer Biology and Signal Transduction Stereospeci fi c PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

  2014cites this paper
• PARP activity in cancer cell lines

  2014cites this paper
• Inhibition of DNA Repair as a Therapeutic Target

  2014cites this paper
• Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

  2014cites this paper
• The antimitotic potential of PARP inhibitors, an unexplored therapeutic alternative.

  2014cites this paper
• Current Overview on the Usage of Poly(ADP-ribose)polymerase (PARP) Inhibitors in Treating Cancer

  2014cites this paper
• Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.

  2014cites this paper
• PARP inhibitors for anticancer therapy.

  2014cites this paper
• Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase

  2014cites this paper
• Poly (ADP-ribose) Polymerase Inhibitors in Cancer Treatment

  2014cites this paper
• Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors.

  2013cites this paper
• BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

  2013cites this paper
• The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies

  2013cites this paper
• Therapeutic Potential of Small Molecule MicroRNA Inhibition.

  2013cites this paper
• PARP and PARP Inhibitor Therapeutics

  2013cites this paper
• Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer

  2013cites this paper
• Expression of PARP1 Gene in Breast Cancer Patients

  2013cites this paper
• “Synthetic Lethality”: Molecular Co-targeting to Restore the DNA Repair Mechanisms in Prostate Cancer Cells

  2013cites this paper
• Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity

  2013cites this paper
• Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer

  2013cites this paper
• Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair

  2013cites this paper
• PARP inhibition potentiates the cytotoxic activity of camptothecin, a topoisomerase I inhibitor in human BRCA1-positive breast cancer cells

  2013cites this paper
• Clinical Significance of PARP-1 Inhibitors in Cancer Chemotherapy

  2013cites this paper
• Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

  2013cites this paper
• Les inhibiteurs de PARP dans le traitement des cancers chimio-résistants : étude pré-clinique sur la dépendance à PARP

  2013cites this paper
• Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

  2013cites this paper
• PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells

  2013cites this paper
• Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer

  2013cites this paper
• Cisplatin resistance associated with PARP hyperactivation.

  2013cites this paper
• Base excision repair of radiation-induced DNA damage in mammalian cells

  2013cites this paper
• Predicting Enhanced Cell Killing through PARP Inhibition

  2012cites this paper
• Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes.

  2012cites this paper
• 3′-5′ Phosphoadenosine phosphate is an inhibitor of PARP-1 and a potential mediator of the lithium-dependent inhibition of PARP-1 in vivo

  2012cites this paper
• Tankyrase-targeted therapeutics: expanding opportunities in the PARP family

  2012cites this paper
• Poly(ADP-ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Mammary Tumors

  2012cites this paper
• Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

  2012cites this paper
• Investigation of the role of poly(ADP-ribose)polymerase inhibition in topoisomerase I poison-induced cytotoxicity

  2012cites this paper
• Ovarian Cancer: Advances in First-Line Treatment Strategies with a Particular Focus on Anti-Angiogenic Agents

  2012cites this paper